MedTrace Logo

Hormones in Hypogonadotropic Hypogonadism

NCT04927676 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-10-23

No results posted yet for this study

Summary

Therefore, the main objective of this prospective pilot study is to evaluate a complete hormonal profile in women with hypogonadotropic hypogonadism, including anti-mullerian hormone (AMH) and antral follicle count. Changes in this regard will be evaluated after 2 months of individual treatment.

Conditions

  • AMH
  • Hypogonadism, Hypogonadotropic
  • Follicle Cyst

Interventions

DIAGNOSTIC_TEST

Blood sample

Blood samples were taken from a peripheral vein as part of clinical routine. Subsequently, a hormone status is determined.

Sponsors & Collaborators

  • Ferring Arzneimittel GmbH

    collaborator INDUSTRY

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Johannes Ott, MD, PhD · Medical University of Vienna

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-02
Primary Completion
2024-06-30
Completion
2024-08-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04927676 on ClinicalTrials.gov